However, data from the immunostaining cohort confirmed the data from the BAL cohort that ADAM15 levels are increased in AMs from patients with COPD versus controls and also demonstrated that the percentage of AMs staining positively for ADAM15 was inversely related to both percent predicted FEV1 and FEV1/FVC. This evidence concerns the gene ADAM15 and chronic obstructive pulmonary disease.